Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Akgun, ZuleyhaHas files: Yes

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    V30 as a predictor for radiation-induced hypothyroidism: a dosimetric analysis in patients who received radiotherapy to the neck
    (BIOMED CENTRAL LTD, 2014-01-01) Akgun, Zuleyha; Atasoy, Beste M.; Ozen, Zeynep; Yavuz, Dilek; Gulluoglu, Bahadir; Sengoz, Meric; Abacioglu, Ufuk
    Introduction: The purpose of this study is to evaluate the possible predictors of thyroid disorders after neck radiotherapy, with a focus on radiation dose-volume factors. Methods: Thyroid function was measured in 100 patients who had received radiotherapy to the neck, including the thyroid. All radiation-induced thyroid dysfunctions were determined with an endpoint of abnormal thyroid stimulating hormone (TSH), free triiodothyronine (fT3) and thyroxine (fT4) and thyroid peroxidase antibodies and (TPA). The total volume of the thyroid, mean radiation dose to the thyroid (Dmean) and thyroid volume percentage that received radiation doses of 10-50 Gy (V10-V50) were calculated in all patients. The evaluated risk factors for thyroid dysfunction included dose-volume parameters, sex, age, previous surgery, chemotherapy and comorbidity. Results: There were 52 patients with hypothyroidism and V30 (p = 0.03), thyroid volume (p = 0.01) and Dmean (p = 0.03) appeared to be correlated with hypothyroidism in univariate analysis. However, there was not association found in multivariate analysis for these factors. Conclusions: Thyroid disorders after radiation therapy to the neck still represent a clinically underestimated problem. V30 may be a useful tool for evaluating the risk of hypothyroidism when determining an individual patient's treatment.
  • Thumbnail Image
    Item
    Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2021-01-01) Yucel, Serap; Kadioglu, Huseyin; Gural, Zeynep; Akgun, Zuleyha; Saglam, Esra Kaytan
    Aims: To evaluate the results of chemoradiation with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) for the treatment of anal canal cancer patients at three institutions that had advanced devices. Materials and Methods: A retrospective analysis was performed for patients treated with 5-fluorouracil and mitomycin-based chemotherapy and IMRT or VMAT for anal cancer from 2011 to 2013. Complete response (CR) rates, colostomy-free survival (CFS), disease-free survival (DFS), overall survival (OS), and toxicities were investigated. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, Version 3.0. Results: Fifteen patients were included in the analysis. The majority of patients had T2 (53.3\%) and N0 (40\%) disease according to the staging system that was developed by the American Joint Committee on Cancer. CR was observed in 14 patients (93\%), and the median follow-up was 26 months (13-42 months). The 3-year CFS, DFS, and OS were 86\%, 86\%, and 88\%, respectively. Acute Grade 3 toxicities were observed as 6\% of hematological, 26\% of gastrointestinal, and 26\% of dermatological. Conclusion: Early results confirm that IMRT or VMAT for anal cancer treatment reduces acute toxicities while maintaining high control rates.